Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. [electronic resource]
Producer: 20100105Description: 5601-6 p. digitalISSN:- 1527-7755
- Administration, Oral
- Adult
- Aged
- Disease-Free Survival
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Fallopian Tube Neoplasms -- drug therapy
- Female
- Humans
- Maximum Tolerated Dose
- Middle Aged
- Neoplasm Recurrence, Local -- drug therapy
- Neoplasms, Glandular and Epithelial -- drug therapy
- Ovarian Neoplasms -- drug therapy
- Peritoneal Neoplasms -- drug therapy
- Prognosis
- Quinazolines -- administration & dosage
- Receptors, Vascular Endothelial Growth Factor -- antagonists & inhibitors
- Risk Assessment
- Survival Analysis
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.